Morgan Stanley
VRAX icon

Morgan Stanley’s Virax Biolabs VRAX Stock Holding History

Morgan Stanley’s Portfolio VRAX Stock Details VRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4
Closed -$225 – 8220
2024
Q4 		$225 Buy
+4
New +$191 ﹤0.01% 7404
2023
Q1 		– Sell
-3
Closed -$623 – 7829
2022
Q4 		$623 Buy
+3
New +$1.07K ﹤0.01% 7536

Other funds holding VRAX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Morgan Stanley's VRAX Position: Q1 2025 in Review

Morgan Stanley sold out of Virax Biolabs (VRAX) in Q1 2025, closing a stake of 4 shares — an estimated $225 sold.

Morgan Stanley first reported a position in VRAX in Q4 2022 and held it in 2 quarters. The position peaked at $623 in Q4 2022. 4 funds tracked by Wall St. Rank hold VRAX as of Q1 2025.

  • Morgan Stanley reported no remaining Virax Biolabs position as of Q1 2025 after selling out during the quarter.
  • Morgan Stanley sold 4 Virax Biolabs shares in Q1 2025, an estimated $225.
  • Morgan Stanley first reported a position in Virax Biolabs in Q4 2022 and held it in 2 quarters.
  • Morgan Stanley's Virax Biolabs position peaked at $623 in Q4 2022.
  • 4 funds tracked by Wall St. Rank held Virax Biolabs as of Q1 2025.

Based on Morgan Stanley's 13F filing for Q1 2025, filed 15 May 2025.